NDAORALCAPSULE
Approved
Feb 2014
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
15
Data completeness
5/8 — Partial
TIVORBEX (indomethacin) by R-Pharm US is cyclooxygenase inhibitors [moa]. Approved for acute gout, patent ductus arteriosus, post-ercp pancreatitis and 2 more indications. First approved in 2014.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TIVORBEX is an oral indomethacin capsule, a cyclooxygenase (COX) inhibitor approved in 2014 for acute gout, patent ductus arteriosus, post-ERCP pancreatitis, acute pancreatitis, and inflammation. It works by inhibiting prostaglandin synthesis to reduce inflammatory response across multiple acute conditions.
Peak4.0 years to LOE
Product is at peak lifecycle stage with stable competitive positioning, suggesting moderate team size focused on market penetration rather than growth initiatives.
Mechanism of Action
Cyclooxygenase Inhibitors
Indications (5)
Worked on TIVORBEX at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.